SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
23
SHAREHOLDER ALERT- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Liberty Health Sciences Inc. (LHSIF) & Lead Plaintiff Deadline: March 8, 2019

NEW YORK, Jan. 14, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Liberty Health Sciences Inc. (“Liberty” or the “Company”) (OTCMKT: LHSIF ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Liberty between June 28, 2018, and December 3, 2018, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/lhsif

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Liberty, in conjunction with Aphria, was involved in a scheme whereby numerous fraudulent acquisitions and transactions were made to provide undue benefits to both companies’ insiders; and (2) as a result, Liberty’s public statements were materially false and misleading at all relevant times.

In September 2018, Aphria announced that it had sold off its stake in Liberty.  On December 3, 2018, Quintessential Capital Management and Hindenburg Research issued a report entitled “Aphria:  A Shell Game with a Cannabis Business on the Side,” claiming that Aphria was part of a scheme involving the acquisition of shell companies at artificially inflated prices. Specifically, the report alleged: “Aphria is part of a scheme orchestrated by a network of insiders to divert funds away from shareholders into their own pockets.”  The article detailed a thorough and on-the-ground investigation into Aphria’s latest investments that revealed the poor quality and worth of the assets of those investments.  For example, the article was accompanied by pictures showing that Aphria’s latest investment in Jamaica was an abandoned building on dilapidated property. Following this news, Liberty’s stock dropped $0.36 per share or nearly 34% over the next two trading days to close at $0.70 on December 4, 2018.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/lhsif or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Liberty you have until March 8, 2019 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Triumph Financial Sets Stage for Q4 Earnings and Insights

Updated Category News Views 196

Triumph Financial Plans Fourth Quarter Earnings Release Triumph Financial, Inc. (Nasdaq: TFIN) recently announced its anticipation for the release of fourth quarter financial results. This event is scheduled to take place after the market closes on an upcoming Wednesday. Along with the financial report, the company will provide management commentary for stakeholders and...

Continue Reading
Monitoring ABA Therapy Progress: A Parent's Guide

Updated Category News Views 6

The Nuts and Bolts of Progress Monitoring You've got a situation in Leominster where parents are trying to make sense of ABA therapy's impact on their kids. Rob Shapiro, a big name in the ABA world, breaks it all down in a HelloNation article. We're talking about precise data collection being the backbone of measuring progress in ABA therapy. This ain't no place for...

Continue Reading
Understanding Dowlais Group's Recent Market Activities

Updated Category News Views 185

Public Disclosure Regarding Dowlais Group's Trading Activity FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose r

Continue Reading
OFS Credit Company Reports Impressive Q4 Financials for 2024

Updated Category News Views 98

OFS Credit Company Delivers Strong Q4 2024 Financial Results OFS Credit Company, Inc. (NASDAQ: OCCI), a notable investment firm focusing on collateralized loan obligation (CLO) equity and debt securities, has announced its financial performance for the fiscal quarter ending October 31, 2024. This report outlines the company’s significant financial growth and strategic...

Continue Reading
Breakthrough Data on HBI-8000 and Nivolumab for Melanoma

Updated Category News Views 89

HBI-8000 and Nivolumab: A New Era in Melanoma Treatment Recent findings highlight the potential of HBI-8000 in combination with nivolumab, suggesting a transformative approach in the treatment of advanced melanoma. This promising combination will be discussed in detail at an upcoming prestigious annual meeting focused on advancements in immunotherapy. Innovative Solutions...

Continue Reading